Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Up 120.0% in April

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 821,485 shares, an increase of 120.0% from the April 15th total of 373,385 shares. Currently, 17.4% of the shares of the stock are sold short. Based on an average trading volume of 52,694,940 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

A number of brokerages recently commented on ASBP. Wall Street Zen upgraded Aspire Biopharma to a “sell” rating in a research report on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a report on Monday, April 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aspire Biopharma has a consensus rating of “Sell”.

Aspire Biopharma Stock Down 4.4%

Aspire Biopharma stock traded down $0.26 during trading hours on Friday, hitting $5.61. The stock had a trading volume of 115,691 shares, compared to its average volume of 1,323,021. Aspire Biopharma has a one year low of $3.31 and a one year high of $1,050.36. The stock has a market cap of $953,700.00, a price-to-earnings ratio of -0.28 and a beta of 0.21. The business’s 50 day simple moving average is $20.67 and its 200-day simple moving average is $90.13.

Aspire Biopharma (NASDAQ:ASBP) last issued its earnings results on Friday, May 15th. The company reported ($20.57) earnings per share for the quarter. The business had revenue of $0.03 million during the quarter.

Hedge Funds Weigh In On Aspire Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC boosted its holdings in Aspire Biopharma by 2,252.1% during the 4th quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock valued at $91,000 after acquiring an additional 658,886 shares during the period. XTX Topco Ltd increased its holdings in shares of Aspire Biopharma by 853.2% in the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after purchasing an additional 237,620 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in shares of Aspire Biopharma in the 3rd quarter worth $28,000. 19.17% of the stock is currently owned by institutional investors.

About Aspire Biopharma

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.